RU2625222C2 - Комбинированная терапия антителом к cd19 и азотистым ипритом - Google Patents

Комбинированная терапия антителом к cd19 и азотистым ипритом Download PDF

Info

Publication number
RU2625222C2
RU2625222C2 RU2014103492A RU2014103492A RU2625222C2 RU 2625222 C2 RU2625222 C2 RU 2625222C2 RU 2014103492 A RU2014103492 A RU 2014103492A RU 2014103492 A RU2014103492 A RU 2014103492A RU 2625222 C2 RU2625222 C2 RU 2625222C2
Authority
RU
Russia
Prior art keywords
seq
bendamustine
lymphoma
antibody
sequence
Prior art date
Application number
RU2014103492A
Other languages
English (en)
Russian (ru)
Other versions
RU2014103492A (ru
Inventor
Ютта АМЕРСДОРФЕР
Штефан Штайдль
Марк ВИНДЕРЛИХ
Сузанне КРОН
Лиза РОЙКЬЕР
Original Assignee
МорфоСис АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by МорфоСис АГ filed Critical МорфоСис АГ
Publication of RU2014103492A publication Critical patent/RU2014103492A/ru
Application granted granted Critical
Publication of RU2625222C2 publication Critical patent/RU2625222C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
RU2014103492A 2011-08-16 2012-08-14 Комбинированная терапия антителом к cd19 и азотистым ипритом RU2625222C2 (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161523861P 2011-08-16 2011-08-16
EP11177658.9 2011-08-16
US61/523,861 2011-08-16
EP11177658 2011-08-16
US201261647539P 2012-05-16 2012-05-16
US61/647,539 2012-05-16
US201261654097P 2012-06-01 2012-06-01
US61/654,097 2012-06-01
PCT/EP2012/065906 WO2013024097A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a nitrogen mustard

Publications (2)

Publication Number Publication Date
RU2014103492A RU2014103492A (ru) 2015-09-27
RU2625222C2 true RU2625222C2 (ru) 2017-07-12

Family

ID=47714801

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014103492A RU2625222C2 (ru) 2011-08-16 2012-08-14 Комбинированная терапия антителом к cd19 и азотистым ипритом

Country Status (24)

Country Link
US (3) US20140255427A1 (https=)
EP (2) EP2744515B1 (https=)
JP (1) JP6184952B2 (https=)
KR (3) KR20200058583A (https=)
CN (1) CN103732252B (https=)
AU (1) AU2012296907B2 (https=)
BR (1) BR112013033919B1 (https=)
CA (2) CA2841875C (https=)
CY (1) CY1125122T1 (https=)
DK (1) DK2744515T3 (https=)
ES (1) ES2909722T3 (https=)
HR (1) HRP20220228T1 (https=)
HU (1) HUE058350T2 (https=)
IL (1) IL230293B (https=)
LT (1) LT2744515T (https=)
MX (1) MX354479B (https=)
PL (1) PL2744515T3 (https=)
PT (1) PT2744515T (https=)
RS (1) RS63238B1 (https=)
RU (1) RU2625222C2 (https=)
SG (1) SG10201606785UA (https=)
SI (1) SI2744515T1 (https=)
SM (1) SMT202200159T1 (https=)
WO (1) WO2013024097A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017519757A (ja) * 2014-06-16 2017-07-20 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． 慢性リンパ球性白血病（ｃｌｌ）の処置
LT3302550T (lt) 2015-05-26 2019-11-11 Morphosys Ag Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas
SMT202100541T1 (it) * 2015-08-21 2021-11-12 Morphosys Ag Combinazioni e loro usi
WO2017172981A2 (en) 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer
RS62155B1 (sr) * 2016-05-30 2021-08-31 Morphosys Ag Postupci predviđanja terapijske koristi anti-cd19 terapije kod pacijenata
IL301786B2 (en) * 2016-10-28 2025-09-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
HRP20231229T1 (hr) * 2017-05-31 2024-02-02 Morphosys Ag Paradigma liječenja za protutijelo anti-cd19 i venetoklaks kombinacijsko liječenje
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
TW202334231A (zh) * 2021-12-22 2023-09-01 德商莫菲西斯公司 抗cd19抗體療法的治療範例

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2228202C2 (ru) * 1998-04-21 2004-05-10 Микромет Аг Cd19xcd3-специфические полипептиды и их применение
WO2007076950A1 (en) * 2005-12-30 2007-07-12 Merck Patent Gmbh Anti-cd19 antibodies with reduced immunogenicity
WO2008022152A2 (en) * 2006-08-14 2008-02-21 Xencor, Inc. Optimized antibodies that target cd19

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
MXPA01011279A (es) * 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
CA2422076A1 (en) 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
JP2008519047A (ja) 2004-11-05 2008-06-05 セフアロン・インコーポレーテツド 癌処置
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
RU2476441C2 (ru) 2007-10-19 2013-02-27 Сиэтл Дженетикс, Инк. Cd19-связывающие средства и их применение
KR20110111303A (ko) * 2009-01-16 2011-10-10 글락소스미스클라인 엘엘씨 벤다무스틴 및 항-ｃｄ２０ 항체의 조합을 이용한 암의 치료
EP2398829A2 (en) 2009-02-23 2011-12-28 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
EP2445530B1 (en) 2009-06-24 2016-09-07 The Feinstein Institute for Medical Research Method for treating chronic lymphocytic leukemia
KR20120054069A (ko) * 2009-08-14 2012-05-29 로슈 글리카트 아게 플루다라빈 및/또는 미토잔트론과 어푸코실화된 ｃｄ20 항체의 복합 요법
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
CA2779424A1 (en) * 2009-11-06 2011-05-12 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2228202C2 (ru) * 1998-04-21 2004-05-10 Микромет Аг Cd19xcd3-специфические полипептиды и их применение
WO2007076950A1 (en) * 2005-12-30 2007-07-12 Merck Patent Gmbh Anti-cd19 antibodies with reduced immunogenicity
WO2008022152A2 (en) * 2006-08-14 2008-02-21 Xencor, Inc. Optimized antibodies that target cd19

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KALOS M. et al., T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia, SCIENCE TRANSLATIONAL MEDICINE, 10 Aug 2011, Vol. 3, Issue 95, pp. 95ra73. *

Also Published As

Publication number Publication date
US20240366756A1 (en) 2024-11-07
MX2013014933A (es) 2014-04-16
RU2014103492A (ru) 2015-09-27
EP2744515B1 (en) 2022-02-09
EP4062936A1 (en) 2022-09-28
AU2012296907B2 (en) 2017-01-05
KR20140064873A (ko) 2014-05-28
CY1125122T1 (el) 2024-12-13
SG10201606785UA (en) 2016-10-28
US20200353077A1 (en) 2020-11-12
PT2744515T (pt) 2022-05-19
SI2744515T1 (sl) 2022-05-31
IL230293B (en) 2019-01-31
JP6184952B2 (ja) 2017-08-23
NZ617770A (en) 2016-01-29
JP2014525926A (ja) 2014-10-02
SMT202200159T1 (it) 2022-05-12
DK2744515T3 (da) 2022-03-28
KR102115203B1 (ko) 2020-05-28
CA2841875A1 (en) 2013-02-21
KR20200058583A (ko) 2020-05-27
CN103732252B (zh) 2017-11-10
CA2841875C (en) 2021-11-02
WO2013024097A1 (en) 2013-02-21
CA3137321A1 (en) 2013-02-21
CN103732252A (zh) 2014-04-16
PL2744515T3 (pl) 2022-05-30
MX354479B (es) 2018-03-07
HUE058350T2 (hu) 2022-07-28
KR20190107749A (ko) 2019-09-20
BR112013033919B1 (pt) 2022-11-16
HRP20220228T1 (hr) 2022-05-13
EP2744515A1 (en) 2014-06-25
ES2909722T3 (es) 2022-05-10
LT2744515T (lt) 2022-04-25
BR112013033919A2 (pt) 2017-12-19
RS63238B1 (sr) 2022-06-30
US20140255427A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
RU2625222C2 (ru) Комбинированная терапия антителом к cd19 и азотистым ипритом
RU2756010C2 (ru) Комбинация антитела к CD19 и ингибитора тирозинкиназы брутона и их применение
RU2664462C2 (ru) Комбинированная терапия с помощью антитела к CD19 и аналога пурина
US12194095B2 (en) Combinations and uses thereof
JP2014525925A5 (https=)
JP2014525926A5 (https=)
AU2012296907A1 (en) Combination therapy with an anti - CD19 antibody and a nitrogen mustard
HK40081594A (en) Combination therapy with an anti-cd19 antibody and a nitrogen mustard
HK40069168A (en) Combinations and uses thereof
NZ617770B2 (en) Combination therapy with an anti - cd19 antibody and a nitrogen mustard

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner